The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Breckenridge Pharmaceutical, Inc. (Breckenridge) is voluntarily performing a Retail Level Class II Recall of **Duloxetine Delayed-Release Capsules, USP, 60mg and 30mg,** manufactured by Towa Pharmaceutical Europe, S.L.

This Retail Level Recall affects **the lots in the table below.**

Only the lots listed in the table below are being recalled due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.

Product	Size	NOC Number	Affected Lot #	Exp Date
Duloxetine Delayed-Release Capsules USP, 60 mg	90-count	51991-748-90	230077C	11/2025
Duloxetine Delayed-Release Capsules USP, 30 mg	90-count	51991-747-90	222205C	11/2025